Infliximab

This chimeric monoclonal antibody targets tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine, and is used to treat a range of inflammatory conditions including rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, and ankylosing spondylitis. It is given by intravenous infusion and can provide significant symptom relief in conditions that have not responded to other treatments. Patients must be screened for tuberculosis before starting treatment.

Yes, Infliximab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.